Shares of biotechnology companies have declined, after the much anticipated American Society of Clinical Oncologists meeting last week in New Orleans. This sector has been on a roll ever since Genentech (NYSE: DNA) vaulted 45% on May 19, 2003 following positive news from Phase III trials of Avastin in colorectal cancer patients. Is the recent correction a good time to fish or cut-bait?
No Load Mutual Funds or Exchange Traded Funds (ETFs)?
If you are fed up with early redemption charges and ever increasing mutual fund management fees on top of bad-performing fund managers, read on. There is a quiet revolution going on in the no-load mutual fund industry and you, the individual investor, may benefit from it greatly.